Literature DB >> 1222761

Allogeneic tumor enhancement by levamisole, a new immunostimulatory compound: studies on cell-mediated immunity and humoral antibody response.

A Mantovani, F Spreafico.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1222761     DOI: 10.1016/0014-2964(75)90125-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  3 in total

1.  Restoration by levamisole of immune responses suppressed in tumor-bearing mice.

Authors:  M Shiraishi; K Himeno; K Nomoto
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

2.  Levamisole augments the cytotoxic T-cell response depending on the dose of drugs and antigen administered.

Authors:  R B Faanes; P Dillon; Y S Choi
Journal:  Clin Exp Immunol       Date:  1977-03       Impact factor: 4.330

3.  Regulation of human natural killing by levamisole.

Authors:  H Shau; J R Dawson
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.